相关实验视频
Updated: Jan 8, 2026
07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
24.2K
术前血miR-144-3p用于预测胃绕道术后持续的2型糖尿病 - - 一项试点概念验证研究
Ana Cristina Martinez1, Dan Linetzky Waitzberg1, Natália Cruz E Melo2
1Laboratory of Nutrition and Metabolic Surgery of the Digestive System (LIM 35), Department of Gastroenterology, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, SP, Brazil.
Diabetes research and clinical practice
|December 12, 2025
概括
术前的miR-144-3p水平可以预测Roux-en-Y胃绕道手术 (RYGB) 后的2型糖尿病 (T2DM) 缓解. 升高的miR-144-3p表明持续T2DM的可能性更高,有助于患者选择.
科学领域:
- 代谢手术 代谢手术
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 鲁克斯-en-Y胃绕道 (RYGB) 提供代谢益处,但并不能保证所有患者的2型糖尿病 (T2DM) 缓解.
- 识别不太可能在RYGB后获得血糖成功的个体仍然是一个临床挑战.
研究的目的:
- 调查手术前循环的microRNAs (miRNAs) 是否可以预测肥胖女性在RYGB后持续的T2DM.
- 为了识别潜在的生物标志物,用于低血糖后的血糖结果.
主要方法:
- 对28名肥胖女性进行RYGB的前性观察队列研究.
- 在手术前和手术后的3,12和60个月内分析血miRNAs.
- TaqMan低密度阵列查,然后对候选miRNA进行RT-qPCR验证.
主要成果:
- 在非响应者 (NR) 与响应者 (R) 相比,在非响应者 (NR) 中观察到术前miR-144-3p表达的升高 (p=0.033).
- 手术前的miR-144-3p预测了具有高特异性的持续T2DM (AUC=0.771,p=0.023).
- 在手术后3个月,较高的miR-144-3p水平与后来的复发有关.
结论:
- 手术前的miR-144-3p是预测RYGB后持续T2DM的一个有希望的候选生物标志物.
- 这一发现可能有助于患者选择和治疗T2DM的治疗策略在减肥手术后.
相关概念视频
01:22Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
01:24Glucagon-like Receptor Agonists
818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818